Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Weight loss pills may fight Cancer-Causing inflammation

NCT ID NCT05756764

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times

Summary

This pilot study looks at how common weight loss medications change inflammatory cells and fats in the blood of 30 obese adults aged 35-60. Researchers want to see if losing weight with drugs like Wegovy or Qsymia reduces chronic inflammation linked to cancer. Participants take standard weight loss meds for 6 months, and their blood is tested before and after.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO

    New Orleans, Louisiana, 70112, United States

  • Ochsner Health System - Biospecimen

    New Orleans, Louisiana, 70121, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Semaglutide, Phentermine-Topiramate, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion

What this could lead to

If successful, this study could reveal how weight loss drugs reduce inflammation, potentially pointing toward ways to lower cancer risk in obese individuals.

What could go wrong

This is a small pilot study with only 30 participants, so results may not apply broadly. It measures markers, not actual cancer outcomes, so any link to cancer prevention is speculative.

Conditions

The condition(s) this trial relates to.

Dyslipidemias Inflammation metabolic syndrome X Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.